• Publications
  • Influence
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results
TLDR
The combined clinimetric results of this study support the validity of the MDS‐UPDRS for rating PD. Expand
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan
TLDR
The MDS‐UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Exper experiences of daily Living; III, Motor Examination; and IV, Motor Complications. Expand
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease
TLDR
The Movement Disorder Society Task Force for Rating Scales for Parkinson's disease (PD) prepared a critique of the Hoehn and Yahr scale, which recommends that it be used in its original form for demographic presentation of patient groups and in research settings, the HY scale is useful primarily for defining inclusion/exclusion criteria. Expand
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
TLDR
Early Parkinson's disease can be managed successfully for up to five years with a reduced risk of dyskinesia by initiating treatment with ropinirole alone and supplementing it with levodopa if necessary. Expand
Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study.
Using functional MRI (fMRI), we have studied the changes induced by the performance of a complex sequential motor task in the cortical areas of six akinetic patients with Parkinson's disease and sixExpand
Depression rating scales in Parkinson's disease: Critique and recommendations
TLDR
A systematic literature review was conducted to explore the use of depression scales in PD and determine which scales should be selected, and found that the complex and time‐consuming task of developing a new scale to measure depression specifically for patients with PD is currently not warranted. Expand
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
TLDR
The objective of this work was to update previous EBM reviews on treatments for PD with a focus on non‐motor symptoms and found that most of the other interventions there is insufficient evidence to make adequate conclusions on their efficacy. Expand
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
TLDR
The objective was to update previous evidence‐based medicine reviews of treatments for motor symptoms of Parkinson's disease published between 2002 and 2005 and highlights gaps for research. Expand
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)
TLDR
The UMSARS appears to be a multidimensional, reliable, and valid scale for semiquantitative clinical assessments of MSA patients. Expand
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised,
TLDR
Once-daily rasagiline reduces mean daily off-time and improves symptoms of Parkinson's disease in levodopa-treated patients with motor fluctuations, an effect similar to that of entacapone. Expand
...
1
2
3
4
5
...